LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC
The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.
Source: onclive.com